Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Labcorp Q2 revenue slightly beats estimates, lifts 2026 outlook 

Labcorp Q2 revenue slightly beats estimates, lifts 2026 outlook 

ReutersReuters2026/07/30 11:01


Overview

  • U.S. laboratory services provider's Q2 revenue up 5.8%, slightly beating analyst expectations

  • Adjusted EPS for Q2 rose 14.9% to $4.99

  • Company raised 2026 revenue growth and adjusted EPS guidance, boosted share buyback by $1.0 bln


Outlook

  • Labcorp raises 2026 enterprise revenue growth guidance to 5.4%-6.3%

  • Company expects 2026 adjusted EPS between $18.10 and $18.55


Result Drivers

  • ORGANIC GROWTH AND OPERATING EFFICIENCIES - Co said increases in adjusted operating income and margin were due to organic growth and operating efficiencies

  • ONCOLOGY AND SPECIALTY TESTING - Co cited expansion in oncology offerings and high-growth specialty areas as drivers of business momentum

  • ACQUISITIONS AND NEW TEST LAUNCHES - Co said acquisitions and launches of new diagnostic tests, including nationwide rollout of ColoSense and new genetic health panels, contributed to growth


Company press release: ID:nPnb5RLPXa


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Revenue

Slight Beat*

$3.73 bln

$3.71 bln (14 Analysts)

Q2 Adj EPS from Cont Ops

$4.99

Q2 EPS from Cont Ops

$3.64

*Applies to a deviation of less than 1%; not applicable for per-share numbers.


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the healthcare facilities services peer group is "buy"

  • Wall Street's median 12-month price target for Labcorp Holdings Inc is $320.00, about 4.2% above its July 29 closing price of $307.15

  • The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 15 three months ago


Reuters Recommended Reads

  • July 28 - NeoGenomics Q2 revenue beats estimates, raises outlook

  • July 29 - GE Healthcare Q2 revenue rises 5.7% on Pharmaceutical Diagnostics unit strength

  • July 28 - IQVIA Q2 revenue beats estimates; outlook raised


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!